GCC19CART for Patients With Metastatic Colorectal Cancer
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Colorectal Cancer
DRUG: GCC19CART
Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation study, Infusion (Day 0) up to Day 28|Maximum tolerable dose (MTD) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study, Infusion (Day 0) up to Day 28|Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study, Infusion (Day 0) up to Day 28
Best overall response as measured by overall response rate based on the tumor size per Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, Infusion (Day 0) up to approximately 12 months or until disease progression/recurrence|Duration of Response (DOR), The duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started)., Infusion (Day 0) up to approximately 12 months|Progression Free Survival (PFS), Progression free survival (PFS) time which is defined as time from date of leukapheresis until the earliest date of disease progression per RECIST 1.1, or death from any cause, whichever comes first., Day 30 (date of leukapheresis) up to approximately 13 months or until the earliest date of disease progression per RECIST 1.1, or death from any cause, whichever comes first.|Overall Survival (OS), Overall survival (OS) is defined as the time from the date of leukapheresis until death from any cause., Day 30 (date of leukapheresis) up to approximately 13 months or until death from any cause|Copy number of Guanylate Cyclase C (GCC) by Quantitative Polymerase Chain Reaction (qPCR), Infusion, Inpatient Monitoring and Post Treatment Period (Up to 12 months)|Copy number of each individual CD19 by Quantitative Polymerase Chain Reaction (qPCR), Infusion, Inpatient Monitoring and Post Treatment Period (Up to 12 months)|Cytokine level in serum, Infusion (Day 0) up to 12 months post treatment|AUC0 - Tmax: The area under curve (AUC) from time zero to Tmax in peripheral blood (days x copies/μg), Infusion (Day 0) up to 12 months post treatment|AUCTmax - 28d and/or AUCTmax - 84d: The area under curve (AUC) from time Tmax to day 28 and/or AUCTmax - 84d or other disease assessment days, in peripheral blood (days x copies/μg), Infusion (Day 0) up to 12 months post treatment|AUC0 - 28d and/or AUC0 - 84d: The area under curve (AUC) from time zero to day 28 and/or day 84 in peripheral blood (days x copies/μg), Infusion (Day 0) up to 12 months post treatment|Cmax: The maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration (copies/μg), Infusion (Day 0) up to 12 months post treatment|Tmax: The time to reach maximum(peak) in peripheral blood or other body fluid drug concentration after single dose administration (days), Infusion (Day 0) up to 12 months post treatment
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.